Centogene (CNTG) News Today → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free CNTG Stock Alerts $0.44 +0.04 (+10.12%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:30 AM | globenewswire.comCENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher DiseaseMay 10, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsMay 10, 2024 | globenewswire.comCENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse PatientsApril 4, 2024 | investing.comCentogene faces Nasdaq delisting over share priceApril 2, 2024 | globenewswire.comCENTOGENE Receives Nasdaq Non-Compliance NoticeMarch 22, 2024 | fool.comCentogene (NASDAQ: CNTG)March 19, 2024 | globenewswire.comCENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersMarch 1, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRa DeficiencyFebruary 29, 2024 | it.investing.comCENTOGENE scopre la carenza del recettore alfa delle cellule pre-TFebruary 29, 2024 | globenewswire.comCENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα DeficiencyFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Explores Strategic AlternativesFebruary 28, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | markets.businessinsider.comCentogene Explores Strategic Alternatives, Incl. SaleFebruary 28, 2024 | markets.businessinsider.comCentogene Announces Receipt Of Nasdaq Notice Of DelistingFebruary 28, 2024 | msn.comCentogene to explores strategic alternatives, gets Nasdaq delisting notice; shares plungeFebruary 28, 2024 | globenewswire.comCENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a HearingFebruary 28, 2024 | globenewswire.comCENTOGENE Explores Strategic AlternativesJanuary 25, 2024 | finanznachrichten.deCentogene NV: CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 25, 2024 | finance.yahoo.comCENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research CollaborationJanuary 24, 2024 | finanznachrichten.deCentogene NV: CENTOGENE Receives French Research Tax Credit AccreditationJanuary 23, 2024 | finance.yahoo.comCENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using MultiomicsJanuary 18, 2024 | finance.yahoo.comCENTOGENE Announces Preliminary Full Year 2023 RevenueDecember 21, 2023 | morningstar.comCentogene NV Ordinary Shares CNTGDecember 13, 2023 | finanznachrichten.deCentogene NV: CENTOGENE's Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneDecember 13, 2023 | msn.comMotus GI, C4 Therapeutics among healthcare moversDecember 13, 2023 | msn.comCCCC, XPOF and AUVI are among pre market gainersDecember 13, 2023 | finance.yahoo.comCENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneNovember 28, 2023 | finanznachrichten.deCentogene NV: CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionNovember 28, 2023 | finance.yahoo.comCENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionOctober 31, 2023 | msn.comEVER, BIVI and CNTG among mid-day moversSeptember 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Centogene NV (CNTG)September 11, 2023 | finance.yahoo.comCENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 7, 2023 | benzinga.comCENTOGENE Reports First Half 2023 Financial ResultsSeptember 1, 2023 | finanznachrichten.deCentogene NV: CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencySeptember 1, 2023 | finance.yahoo.comCENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease PatientsAugust 31, 2023 | finance.yahoo.comCENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyAugust 7, 2023 | finance.yahoo.comCENTOGENE to Participate in Upcoming Conferences in AugustJuly 14, 2023 | finanznachrichten.deCentogene NV: CENTOGENE Regains Compliance With Nasdaq Listing RequirementsJuly 12, 2023 | finanznachrichten.deCentogene NV: CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease CohortJuly 12, 2023 | technews.tmcnet.comCENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease CohortJuly 2, 2023 | finance.yahoo.comLifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic TestingJuly 1, 2023 | finanznachrichten.deCentogene NV: CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General MeetingJune 30, 2023 | finance.yahoo.comCENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General MeetingJune 28, 2023 | msn.comHC Wainwright & Co. Reiterates Centogene (CNTG) Buy RecommendationJune 28, 2023 | markets.businessinsider.comAnalyst Expectations for Centogene's FutureJune 27, 2023 | msn.comCNTG Skyrockets after Strategic JV with LiferaJune 27, 2023 | msn.comWhy Centogene (CNTG) Stock Is Roaring Higher TuesdayJune 27, 2023 | marketbeat.comTrading was temporarily halted for "CNTG" at 07:06 AM with a stated reason of "News pending."June 14, 2023 | finance.yahoo.comCENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares DeficiencyMay 18, 2023 | msn.comHC Wainwright & Co. Maintains Centogene (CNTG) Buy Recommendation Get Centogene News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. CNTG Media Mentions By Week CNTG Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTG News Sentiment▼0.460.56▲Average Medical News Sentiment CNTG News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTG Articles This Week▼61▲CNTG Articles Average Week Get Centogene News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACONW News DRTSW News AONC News ARTLW News BIAFW News BCTXW News BFRGW News CCLDP News CCLDO News CCM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTG) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centogene Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
